The certificate of source validation is valid for 3 years from date of issue.

Kimia Biosciences gets recognition for supply of pharmaceutical raw material to Bangladesh

Kimia Biosciences hit an upper circuit limit of 20% at Rs 56 after the company said it has been validated for supplying pharmaceutical raw material (Bilastine) to Bangladesh.

Kimia Biosciences hits the roof after validation in Bangladesh

Buzzing stocks: Banks, NMDC, Lambodhara Textiles, Deep Industries, Puravankara, Varun Beverages, KPI Global, Pioneer Embroideries, Rane Holdings, Kimia Biosciences

Stocks that will see action today

Kimia Biosciences reports standalone net loss of Rs 1.27 crore in the September 2021 quarter

Kimia Biosciences standalone net profit declines 83.84% in the June 2021 quarter

Kimia Biosciences reports standalone net loss of Rs 0.91 crore in the March 2021 quarter

BRIEF-Kimia Biosciences Says Sameer Goel Reappointed Chairman & MD

BRIEF-Kimia Biosciences Says Got India Drug Regulator Nod To Manufacture Bilastine

BRIEF-Kimia Biosciences Gets India Drug Regulator Nod To Manufacture Brivaracetam For Sale Or Distribution

Antony Waste Handling Cell, Welspun Corp, UPL, Infibeam Avenues, Birla Tyres, General Insurance Corporation of India, Time Technoplast, Zeal Aqua, Flexituff Ventures International, Kimia Biosciences, CRISIL Ratings, Arihant Superstructures, IDBI Bank, Godrej Agrovet, HealthCare Global Enterprises, N…

Stocks In The News | Wellesley Corporation, Dredging Corporation, HSIL, IRCTC, Barak Valley Cements, Pricol

The Financial News section features stock market news in addition to stories about bonds, forex, commodities and economic releases.

BRIEF-Kimia Biosciences Gets Permission To Manufacture And Market ‘Obeticholic Acid’ - Investing.com India

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Average profitability - not good, not bad

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

The company makes bulk drug intermediates. It manufactures bulk drugs intermediates for Indian pharmaceutical companies on contract manufacturing basis. It also offers finish goods and fine chemicals.